Tivantinib

DRUG19 trials

Sponsors

Daiichi Sankyo, ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), National Cancer Institute (NCI), SCRI Development Innovations, LLC, Armando Santoro, MD

Conditions

Adult Solid NeoplasmAdvanced Solid TumorsCancerChildhood Solid NeoplasmEpithelioid MesotheliomaEstrogen Receptor NegativeGastroesophageal CancerHER2/Neu Negative

Phase 1

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

CompletedNCT01075048

Daiichi SankyoMetastatic Colorectal Cancer

Start: 2010-01-26End: 2015-02-20Updated: 2021-04-08

An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols

CompletedNCT01178411

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Advanced Solid Tumors

Start: 2010-08-31End: 2019-01-14Updated: 2021-03-10

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

CompletedNCT01517399

Daiichi SankyoSolid Tumors

Start: 2011-12-31End: 2013-09-30Updated: 2019-02-12

Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach

CompletedNCT01611857

SCRI Development Innovations, LLCGastroesophageal Cancer, Malignant Solid Tumour

Start: 2012-07-31End: 2015-08-31Updated: 2016-11-23

Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery

CompletedNCT01625156

National Cancer Institute (NCI)Adult Solid Neoplasm

Start: 2012-05-31End: 2015-10-31Updated: 2015-10-20

Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors

CompletedNCT01654965

National Cancer Institute (NCI)Adult Solid Neoplasm

Start: 2012-07-24End: 2018-03-29Updated: 2018-04-03

Effect of Tivantinib on the QTC Interval in Cancer Subjects

CompletedNCT01699061

Daiichi SankyoSolid Tumors

Start: 2012-07-31End: 2013-05-31Updated: 2019-02-12

Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors

CompletedNCT01725191

National Cancer Institute (NCI)Childhood Solid Neoplasm

Start: 2012-10-31End: 2015-05-31Updated: 2015-07-02

Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

CompletedNCT01749384

National Cancer Institute (NCI)Solid Neoplasm

Start: 2012-12-06End: 2016-05-24Updated: 2017-10-12

Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin

CompletedNCT02049060

Armando Santoro, MDMalignant Pleural Mesothelioma, Nonsquamous Nonsmall Cell Neoplasm of Lung

Start: 2013-01-31End: 2017-12-31Updated: 2021-01-22

Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment

CompletedNCT02150733

Daiichi SankyoCancer, Hepatic Impairment, Solid Tumor

Start: 2014-04-30End: 2016-07-31Updated: 2019-02-12

Phase 2

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

CompletedNCT01447914

National Cancer Institute (NCI)Refractory Multiple Myeloma

Start: 2011-11-30End: 2014-04-30Updated: 2019-08-28

Tivantinib in Treating Patients With Metastatic Prostate Cancer

CompletedNCT01519414

National Cancer Institute (NCI)Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma +1

Start: 2012-01-11End: 2015-08-18Updated: 2018-09-12

Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer

CompletedNCT01575522

National Cancer Institute (NCI)Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative +3

Start: 2012-03-31End: 2013-07-31Updated: 2016-03-21

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery

CompletedNCT01688973

National Cancer Institute (NCI)Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer +2

Start: 2012-08-20End: 2017-04-30Updated: 2019-01-03

Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery

CompletedNCT01696955

National Cancer Institute (NCI)Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma

Start: 2012-08-20End: 2017-05-05Updated: 2018-12-19

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

TerminatedNCT01861301

National Cancer Institute (NCI)Epithelioid Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma +3

Start: 2013-01-31End: 2015-03-31Updated: 2016-10-24

Phase 3

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

TerminatedNCT01244191

Daiichi SankyoNon Squamous, Non-small-cell Lung Cancer

Start: 2011-01-11End: 2012-12-15Updated: 2021-04-06

Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy

CompletedNCT01755767

Daiichi SankyoHepatocellular Carcinoma

Start: 2012-12-27End: 2017-07-31Updated: 2021-04-06

Related Papers

A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with MET overexpression treated with gumarontinib.

2024-07-311 citations

Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors.

2021-06-233 citations

A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma

Therapeutic Advances in Medical Oncology2019-01-0158 citations

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

2018-04-03266 citations

Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIV-HCC phase III trial.

Journal of Clinical Oncology2017-05-2040 citations

Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date.

2016-11-1518 citations

A randomized phase II trial of the MET inhibitor tivantinib + cetuximab versus cetuximab alone in patients with recurrent/metastatic head and neck cancer.

Journal of Clinical Oncology2015-05-2021 citations

SWOG 1107: Parallel (randomized) phase II evaluation of tivantinib (ARQ-197) and tivantinib in combination with erlotinib in patients (Pts) with papillary renal cell carcinoma (pRCC).

Journal of Clinical Oncology2015-05-2014 citations

A phase II study of the c-Met inhibitor tivantinib (tiv) in combination with FOLFOX for the treatment of patients (pts) with previously untreated metastatic adenocarcinoma of the distal esophagus, gastroesophageal (GE) junction, or stomach.

Journal of Clinical Oncology2015-05-2010 citations

Phase I trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients with advanced nonsquamous non small cell lung cancer or malignant pleural mesothelioma.

Journal of Clinical Oncology2015-05-205 citations

A phase I study of ARQ 197 in combination with temsirolimus in advanced solid tumors.

Journal of Clinical Oncology2015-05-20

Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2015-03-018 citations

Biopsy for liver cancer: How to balance research needs with evidence‐based clinical practice

Hepatology2014-10-1241 citations

Phase I-Ib trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients (pts) with advanced nonsquamous NSCLC or malignant pleural mesothelioma (MPM).

Journal of Clinical Oncology2014-05-204 citations

A phase 1 study of the c-Met inhibitor tivantinib (ARQ 197, IND#112603) in children with relapsed or refractory solid tumors: A Children’s Oncology Group study.

Journal of Clinical Oncology2014-05-201 citations

The effect of tivantinib on QTc interval in subjects with advanced solid tumors and healthy subjects.

Journal of Clinical Oncology2014-05-20

Abstract C85: Drug interaction study of tivantinib in cancer subjects using a cocktail approach.

Molecular Cancer Therapeutics2013-11-01